Key result
Combination therapy with aspirin and dipyridamole for 2 months reduced proteinuria by 37.3% in patients with type-2 diabetic nephropathy, compared to a 1.9% increase with placebo.
Why the study?
Does short-term therapy with aspirin, dipyridamole, or their combination reduce proteinuria in patients with type-2 diabetic nephropathy?
Population
76 patients with type-2 diabetic nephropathy and normal renal function tests
Comparison
Aspirin, dipyridamole, or their combination… vs Placebo daily for 2 months
Design
RCT, randomized into 4 groups, placebo-controlled
Follow-up
2 months
Authors
Loading...
Short-term antiplatelet therapy may reduce proteinuria in type-2 diabetic nephropathy; larger trials needed to assess renal outcomes.
RCT (n=76)
placebo-controlled
randomized
Does short-term therapy with aspirin, dipyridamole, or their combination reduce proteinuria in patients with type-2 diabetic nephropathy?
Absolute Event Rate: -37.3% vs 1.9%
p-value: p=0.0007
Short-term therapy with aspirin and/or dipyridamole, especially in combination, significantly reduces proteinuria in patients with type-2 diabetic nephropathy.
Khajehdehi et al. (2002) conducted an RCT in type-2 diabetic nephropathy (n=76). Aspirin, dipyridamole, or their combination vs. Placebo was evaluated on Percentage proteinuria change (p=0.0007). Combination therapy with aspirin and dipyridamole for 2 months reduced proteinuria by 37.3% in patients with type-2 diabetic nephropathy, compared to a 1.9% increase with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: